Antidiabetic, antihyperlipidemic and anti-inflammatory effects of tilianin in streptozotocin-nicotinamide diabetic rats

Biomedicine and Pharmacotherapy

Volumn 83, Issue , 2016, Pages 667-675

  García Díaz, Jorge Alberto ^a   Navarrete Vázquez, Gabriel ^a   García Jiménez, Sara ^a   Hidalgo Figueroa, Sergio ^b   Almanza Pérez, Julio C ^b   Alarcón Aguilar, Francisco Javier ^b   Gómez Zamudio, Jaime ^c   Cruz, Miguel ^c   Ibarra Barajas, Maximiliano ^d   Estrada Soto, Samuel ^a  

^a UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS   (Mexico)

^b DEPARTAMENTO DE QUÍMICA   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Adiponectin; Flavones; NIDDM model; PPAR ; Tilianin

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; CELL ADHESION MOLECULE; CHOLESTEROL; COMPLEMENTARY DNA; GLUCOSE; GLUCOSE TRANSPORTER 4; GLUTAMIC ACID; INTERLEUKIN 18; INTERLEUKIN 1BETA; MESSENGER RNA; METFORMIN; NICOTINAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STREPTOZOCIN; TILIANIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; UNCLASSIFIED DRUG; FATTY ACID; FLAVONOID; GLUCOSE BLOOD LEVEL; GLYCOSIDE;

ADIPOCYTE; ADIPOSE TISSUE; AGASTACHE; AGASTACHE MEXICANA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AORTIC TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DETERMINATION; EXPERIMENTAL ANIMAL; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SHORT COURSE THERAPY; STREPTOZOTOCIN NICOTINAMIDE INDUCED NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WISTAR RAT; 3T3 CELL LINE; ANIMAL; AORTA; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LIPOGENESIS; METABOLISM; MOUSE; OXIDATION REDUCTION REACTION;

3T3-L1 CELLS; ADIPOSE TISSUE; ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; FATTY ACIDS; FLAVONOIDS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLYCOSIDES; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; LIPOGENESIS; MALE; METFORMIN; MICE; MOLECULAR DOCKING SIMULATION; NIACINAMIDE; OXIDATION-REDUCTION; RATS, WISTAR; STREPTOZOCIN;

EID: 84979272966     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.07.023     Document Type: Article

References (36)

1. [1] Stern, M.P., Strategies and prospects for finding insulin resistance genes. J. Clin. Invest. 106 (2000), 323–327.
2. [2] Groop, L., Pociot, F., Genetics of diabetes—are we missing the genes or the disease?. Mol. Cell. Endocrinol. 382 (2014), 726–739.
3. [3] Pickup, J.C., Crook, M.A., Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia 41 (1998), 1241–1248.
4. [4] Leiherer, A., Mϋndlein, A., Drexel, H., Phytochemicals and their impact on adipose tissue inflammation and diabetes. Vascul. Pharmacol. 58 (2013), 3–20.
5. [5] Babu, P.V., Liu, D., Gilbert, E.R., Recent advances in understanding the anti-diabetic actions of dietary flavonoids. J. Nutr. Biochem. 24 (2013), 1777–1789.
6. [6] Caselli, C., Role of adiponectin system in insulin resistance. Mol. Genet. Metab. 113 (2014), 155–160.
7. [7] Moller, D.E., Berger, J.P., Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int. J. Obes. Relat. Metab. Disord. 27 (2003), S17–S21.
8. [8] Deepa, S.S., Dong, L.Q., APPL1: role in adiponectin signaling and beyond. Am. J. Physiol. Endocrinol. Metab. 296 (2009), E22–E36.
9. [9] Hernández-Abreu, O., Castillo-España, P., León-Rivera, I., Ibarra-barajas, M., Villalobos-Molina, R., González-Christen, J., Vergara-Galicia, J., Estrada-Soto, S., Antihypertensive and vasorelaxant effects of tilianin isolated from Agastache mexicana are mediated by NO/cGMP pathway and potassium channel opening. Biochem. Pharmacol. 78 (2009), 54–61.
10. [10] Hong, J.J., Choi, J.H., Oh, S.R., Lee, H.K., Park, J.H., Lee, K.Y., Kim, J.J., Jeong, T.S., Oh, G.T., Inhibition of cytokine-induced vascular cell adhesion molecule-1 expression; possible mechanism for anti-atherogenic effect of Agastache rugosa. FEBS Lett. 495 (2001), 142–147.
11. [11] Nam, K.W., Kim, J., Hong, J.J., Choi, J.H., Mar, W., Cho, M.H., Kim, Y.M., Oh, S.R., Lee, H.K., Nam, K.H., Oh, G.T., Inhibition of cytokine-induced IkappaB kinase activation as a mechanism contributing to the anti-atherogenic activity of tilianin in hyperlipidemic mice. Atherosclerosis 180 (2005), 27–35.
12. [12] Nam, K.H., Choi, J.H., Seo, Y.J., Lee, Y.M., Won, Y.S., Lee, M.R., Lee, M.N., Park, J.G., Kim, Y.M., Kim, H.C., Lee, C.H., Lee, H.K., Oh, S.R., Oh, G.T., Inhibitory effects of tilianin on the expression of inducible nitric oxide synthase in low density lipoprotein receptor deficiency mice. Exp. Mol. Med. 38 (2006), 445–452.
13. [13] Hernández-Abreu, O., Durán-Gómez, L., Best-Brown, R., Villalobos-Molina, R., Rivera-Leyva, J.C., Estrada-Soto, S., Validated liquid chromatographic method and analysis of content of tilianin on several extracts obtained from Agastache mexicana and its correlation with vasorelaxant effect. J. Ethnopharmacol. 138 (2011), 487–491.
14. [14] Ortiz-Andrade, R.R., Rodríguez-López, V., Garduño-Ramírez, M.L., Castillo-España, P., Estrada-Soto, S., Antidiabetic effect on alloxanized and normoglycemic rats and some pharmacological evaluations of Tournefortia hartwegiana. J. Ethnopharmacol. 101 (2005), 37–42.
15. [15] Chomczynski, P., Sacchi, N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162 (1987), 156–159.
16. [16] Green, H., Kehinde, O., An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. Cell 5 (1975), 19–27.
17. [17] Garcia-Macedo, R., Sanchez-Muñoz, F., Almanza-Pérez, J.C., Duran-Reyes, G., Alarcon-Aguilar, F., Cruz, M., Glycine increases mRNA adiponectin and diminishes pro-inflammatory adipokines expression in 3T3-L1 cells. Eur. J. Pharmacol. 587 (2008), 317–321.
18. [18] Olivares-Reyes, J.A., Arellano-Plancarte, A., Castillo-Hernández, J.R., Angiotensin II and the development of insulin resistance: implications for diabetes. Mol. Cell. Endocrinol. 302 (2009), 128–139.
19. [19] Fernández-Veledo, S., Nieto-Vazquez, I., de Castro, J., Ramos, M.P., Brϋderlein, S., Mӧller, P., Lorenzo, M., Hyperinsulinemia induces insulin resistance on glucose and lipid metabolism in a human adipocytic cell line: paracrine interaction with myocytes. J. Clin. Endocrinol. Metab. 93 (2008), 2866–2876.
20. [20] Deiuliis, J., Shah, Z., Shah, N., Needleman, B., Mikami, D., Narula, V., Perry, K., Hazey, J., Kampfrath, T., Kollengode, M., Sun, Q., Satoskar, A.R., Lumeng, C., Moffatt-Bruce, S., Rajagopalan, S., Visceral adipose inflammation in obesity is associated with critical alterations in tregulatory cell numbers. PLoS One, 6, 2011, e16376.
21. [21] Tilg, H., Moschen, A.R., Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6 (2006), 772–783.
22. [22] Vinayagam, R., Xu, B., Antidiabetic properties of dietary flavonoids: a cellular mechanism review. Nutr. Metab. 12:60 (2015), 1–20.
23. [23] Luo, C., Yang, H., Tang, C., Yao, G., Kong, L., He, H., Zhou, Y., Kaempferol alleviates insulin resistance via hepatic IKK/NF-κB signal in type 2 diabetic rats. Int. Immunopharmacol. 28 (2015), 744–750.
24. [24] Mena, P., Domínguez-Perles, R., Gironés-Vilaplana, A., Baenas, N., García-Viguera, C., Villaño, D., Flavan-3-ols, anthocyanins, and inflammation. IUBMB Life 66 (2015), 745–758.
25. [25] Ortiz-Andrade, R., Sánchez-Salgado, J.C., Navarrete-Vázquez, G., Webster, S.P., Binnie, M., García-Jiménez, S., León-Rivera, I., Cigarroa-Vázquez, P., Villalobos-Molina, R., Estrada-Soto, S., Antidiabetic and toxicological evaluations of naringenin in Normoglycemic And NIDMM rat models and its implications on extra-pancreatic glucose regulation. Diabetes Obes. Metab. 10 (2008), 1097–1104.
26. [26] Torres-Piedra, M., Ortiz-Andrade, R., Villalobos-Molina, R., Singh, N., Medina-Franco, J.L., Webster, S.P., Binnie, M., Navarrete-Vázquez, G., Estrada-Soto, S., A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11β-hydroxysteroid dehydrogenase type 1 Inhibition. Eur. J. Med. Chem. 45 (2010), 2606–2612.
27. [27] Trayhurn, P., Wood, I.S., Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br. J. Nutr. 92 (2004), 347–355.
28. [28] Benzler, Jonas, Ganjam, G.K., Pretz, D., Oelkrug, R., Koch, C.E., Legler, K., Stöhr, Sigrid, Culmsee, C., Williams, L.M., Tups, A., Central inhibition of IKKö/NF-βB signaling attenuates high-fat diet-induced obesity and glucose intolerance. Diabetes 64 (2015), 2015–2027.
29. [29] Li, Y., Yan, H., Zhang, Z., Zhang, G., Sun, Y., Yu, P., Wang, Y., Xu, L., Andrographolide derivative AL-1 improves insulin resistance through down-regulation of NF-κB signalling pathway. Br. J. Pharmacol. 172 (2015), 3151–3158.
30. [30] Bruun, J.M., Stallknecht, B., Helge, J.W., Richelsen, B., Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur. J. Endocrinol. 157 (2007), 465–471.
31. [31] Kalupahana, N.S., Moustaid-Moussa, N., Claycombe, K.J., Immunity as a link between obesity and insulin resistance. Mol. Aspects Med. 33 (2012), 26–34.
32. [32] Kothari, V., Galdo, J.A., Mathews, S.T., Hypoglycemic agents and potential anti-inflammatory activity. J. Inflamm. Res. 9 (2016), 27–38.
33. [33] Schalkwijk, C.G., Stehouwer, C.D., Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin. Sci. 109 (2005), 143–159.
34. [34] Shanmugam, N., Gaw Gonzalo, I.T., Natarajan, R., Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocyte. Diabetes 53 (2004), 795–802.
35. [35] Kassan, M., Choi, S.K., Galán, M., Bishop, A., Umezawa, K., Trebak, M., Belmadani, S., Matrougui, K., Enhanced NF-κB activity impairs vascular function through PARP-1-, SP-1-, and COX-2-dependent mechanism in type 2 diabetes. Diabetes 62 (2013), 2078–2087.
36. [36] Guerre-Millo, M., Gervois, P., Raspé, E., Madsen, L., Poulain, P., Derudas, B., Herbert, J.M., Winegar, D.A., Willson, T.M., Fruchart, J.C., Berge, R.K., Staels, B., Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275 (2000), 16638–16642.